Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial
European Journal of Cancer2019Vol. 112, pp. 57–65
Citations Over TimeTop 10% of 2019 papers
Peng Yuan, Xichun Hu, Tao Sun, Wei Li, Qingyuan Zhang, Shude Cui, Ying Cheng, Quchang Ouyang, Xiaojia Wang, Zhendong Chen, Masahide Hiraiwa, Kenichi Saito, Setsuo Funasaka, Binghe Xu
Related Papers
- → Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial(2019)87 cited
- → A phase II trial of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer(2009)1 cited
- → Eribulin in combination with bevacizumab as second-line treatment for HER2–negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)(2020)1 cited
- Clinical observation of vinorelbine plus cisplatin in treatment of recurrent metastatic breast cancer failed taxane chemotherapy(2010)
- Recent Efficacy and Safety of Gemcitabine and Vinorelbine Combination Chemotherapy for Patients with Anthracycline and Taxane-Resistant Metastatic Breast Cancer(2012)